clinical trial · NCT05236673
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
Heart FailureJARDIANCE®
brief summary
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
started
Jul 28, 2022
primary completion
Apr 30, 2025
completion
Apr 30, 2025
last updated
Aug 10, 2026
official title
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Jardiance® (Empagliflozin, 10mg) in Korean Patients With Chronic Heart Failure (NYHA Class II-IV)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol